Reviewing PureTech Health (NASDAQ:PRTC) and GlycoMimetics (NASDAQ:GLYC)

PureTech Health (NASDAQ:PRTC) and GlycoMimetics (NASDAQ:GLYC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares PureTech Health and GlycoMimetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PureTech Health	N/A	N/A	N/A
GlycoMimetics	N/A	-160.93%	-132.85%

Analyst Ratings

This is a summary of current recommendations for PureTech Health and GlycoMimetics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PureTech Health	0	0	1	1	3.50
GlycoMimetics	0	3	0	0	2.00

PureTech Health currently has a consensus target price of $45.00, indicating a potential upside of 134.24%. GlycoMimetics has a consensus target price of $8.00, indicating a potential upside of 2,852.03%. Given GlycoMimetics’ higher possible upside, analysts clearly believe GlycoMimetics is more favorable than PureTech Health.

Valuation and Earnings

This table compares PureTech Health and GlycoMimetics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PureTech Health	$3.33 million	138.11	-$65.70 million	N/A	N/A
GlycoMimetics	$10,000.00	1,747.41	-$36.90 million	N/A	N/A

GlycoMimetics has lower revenue, but higher earnings than PureTech Health.

Insider and Institutional Ownership

0.0% of PureTech Health shares are owned by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are owned by institutional investors. 5.3% of PureTech Health shares are owned by company insiders. Comparatively, 8.7% of GlycoMimetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

PureTech Health has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, GlycoMimetics has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

About GlycoMimetics

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.